Ovid Therapeutics Inc. Common Stock

OVIDNASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
2.40 USD
↘ 0.08 (3.23%)AT CLOSE (11:59 AM EDT)
2.39
↘ 0.01 (0.25%)
POST MARKET (AS OF 06:45 PM EDT)
Post Market
AS OF 06:45 PM EDT
2.39
↘ 0.01 (0.25%)
🔴Market: CLOSED
Open?$2.46
High?$2.46
Low?$2.36
Prev. Close?$2.48
Volume?1.4M
Avg. Volume?1.7M
VWAP?$2.40
Rel. Volume?0.83x
Bid / Ask
Bid?$2.07 × 100
Ask?$2.76 × 100
Spread?$0.69
Midpoint?$2.42
Valuation & Ratios
Market Cap?447.9M
Shares Out?186.6M
Float?97.7M
Float %?75.0%
P/E Ratio?N/A
P/B Ratio?2.26
EPS?-$0.13
Dividend?0.00%
Ex-Dividend?N/A

Ovid Therapeutics Inc. Common Stock (OVID) trades at $2.40 per share. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. OVID is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Themes
Biotech - Drug Development›Neuroscience & CNSBiotech - Drug Development›Rare Disease Therapeutics
Employees
23
Market Cap
447.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.ovidrx.com
Listed
2017-05-05
Address
441 NINTH AVENUE, 14TH FLOOR
NEW YORK, NY 10001
Phone: 212-776-4381
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
30
Piotroski F-Score?0/9Weak
Altman Z-Score?7.82Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.33%High
Short Interest?10.1M
Days to Cover?4.6
Free Float97.7M
Avg Daily Volume2.2M
Settlement Date2026-05-15
Financial Health
Current Ratio?10.17Strong
Quick Ratio?10.17Strong
Cash Ratio?5.97Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
69
2.26CHEAP▾
P/S?
Peers
100
S&P
3
62.89HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-7.4CHEAP▾
EV/Sales?
Peers
100
S&P
3
49.69HIGH▾
Returns & Efficiency
ROE?
S&P
9
-12.2%WEAK▾
ROA?
S&P
3
-10.7%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$353.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist